Yili Chuanning Biotechnology Co.,Ltd. (SHE: 301301)

Market Cap	24.16B
Revenue (ttm)	5.60B
Net Income (ttm)	1.32B
Shares Out	2.23B
EPS (ttm)	0.58
PE Ratio	18.80
Forward PE	16.61
Dividend	0.22 (2.09%)
Ex-Dividend Date	May 22, 2024

Volume	23,239,922
Open	10.69
Previous Close	10.75
Day's Range	10.68 - 10.97
52-Week Range	6.94 - 18.33
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Yili Chuanning Biotechnology Co.,Ltd.

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 2,881
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2023, Yili Chuanning Biotechnology Co.,Ltd.'s revenue was 4.82 billion, an increase of 26.24% compared to the previous year's 3.82 billion. Earnings were 940.56 million, an increase of 128.56%.